- Home
- CDIO vs AIOS Comparison
CDIO vs AIOS Comparison
Compare CDIO & AIOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDIO | AIOS |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | China |
| Employees | 17 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CDIO | AIOS |
|---|---|---|
| Price | $2.15 | $15.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 73.3K | ★ 240.0K |
| Earning Date | 05-13-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $171,906.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.39 |
| 52 Week High | $7.91 | $33.87 |
Technical Indicators
Market Signals| Indicator | CDIO | AIOS |
|---|---|---|
| Relative Strength Index (RSI) | 63.97 | 57.05 |
| Support Level | $1.68 | $13.01 |
| Resistance Level | $2.35 | $18.80 |
| Average True Range (ATR) | 0.17 | 2.03 |
| MACD | 0.08 | -0.65 |
| Stochastic Oscillator | 96.28 | 49.57 |
Price Performance
Historical ComparisonAbout CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.